Doxorubicin concentrations in bone tumour-relevant tissues after bolus and continuous infusion: a randomized porcine microdialysis study Andrea René JørgensenMats BueMaiken Stilling Original Article Open access 08 February 2024 Pages: 555 - 564
Effect of lithium on chemotherapy-induced neutropenia in Egyptian breast cancer patients; a prospective clinical study Ahmed O. ELKasarFatma Z. HussienAdel R. Abd-Allah Original Article 07 February 2024 Pages: 541 - 554
UGT1A4 Polymorphism is not Associated with a Clinically Relevant Change in Giredestrant Exposure Vikram MalhiMalgorzata NowickaJiajie Yu Short Communication Open access 02 February 2024
The landscape of very important pharmacogenes variants and potential clinical relevance in the Chinese Jingpo population: a comparative study with worldwide populations Xiaoya MaYujie LiTianbo Jin Original Article 01 February 2024 Pages: 481 - 496
Pharmacokinetics/pharmacodynamics of ivosidenib in advanced IDH1-mutant cholangiocarcinoma: findings from the phase III ClarIDHy study Bin FanGhassan K. Abou-AlfaHua Yang Original Article Open access 27 January 2024 Pages: 471 - 479
Expression of molecular markers and synergistic anticancer effects of chemotherapy with antimicrobial peptides on glioblastoma cells Alexandr N. ChernovAlexandr V. KimOlga V. Shamova Original Article 27 January 2024 Pages: 455 - 469
Midostaurin drug interaction profile: a comprehensive assessment of CYP3A, CYP2B6, and CYP2C8 drug substrates, and oral contraceptives in healthy participants Romain SechaudHelen GuHans D. Menssen Original Article 25 January 2024 Pages: 439 - 453
Correction to: Up-regulation of autophagy is a mechanism of resistance to chemotherapy and can be inhibited by pantoprazole to increase drug sensitivity Qian TanA. M. JoshuaIan F. Tannock Correction 19 January 2024
Evaluation of ABT-751, a novel anti-mitotic agent able to overcome multi-drug resistance, in melanoma cells Thamir M. MahgoubEmmet J. JordanDenis M. Collins Original Article Open access 16 January 2024 Pages: 427 - 437
Phase I study of the anti-TIGIT antibody tiragolumab in combination with atezolizumab in Japanese patients with advanced or metastatic solid tumors Noboru YamamotoTakafumi KoyamaToshio Shimizu Short Communication Open access 11 January 2024
Ruthenium–dihydroartemisinin complex: a promising new compound for colon cancer prevention via G1 cell cycle arrest, apoptotic induction, and adaptive immune regulation Chong-Zhi WangChunping WanChun-Su Yuan Original Article 09 January 2024 Pages: 411 - 425
Inhibition of proteinase-activated receptor 2 (PAR2) decreased the malignant progression of lung cancer cells and increased the sensitivity to chemotherapy Hongjie HuoYu FengQiong Tang Original Article Open access 04 January 2024 Pages: 397 - 410
Bioequivalence, food effect and comparative pharmacokinetics of SUVN-1105, a novel granule formulation of abiraterone acetate, to Zytiga in healthy male subjects Ramakrishna NirogiJyothsna RavulaVeera Raghava Chowdary Palacharla Original Article 29 December 2023 Pages: 253 - 264
Evaluation of mycophenolic acid exposure in a patient with immune-related hepatotoxicity caused by nivolumab and ipilimumab therapy for malignant melanoma: a case report Yoshiharu SuzukiShingo IshiguroMika Suzuki Short Communication 26 December 2023 Pages: 633 - 638
Andrographolide inhibits Burkitt’s lymphoma by binding JUN and CASP3 proteins Junquan ZengYongliang ZhengTingting Liu Original Article Open access 26 December 2023 Pages: 381 - 391
Parthenolide inhibits the proliferation and migration of cervical cancer cells via FAK/GSK3β pathway Liru HuangFuhong LiuPing Hu Original Article 23 December 2023 Pages: 203 - 213
Retraction Note: Atrial natriuretic peptide protects against cisplatin‑induced granulocytopenia Takashi NojiriHiroshi HosodaKenji Kangawa Retraction Note 21 December 2023 Pages: 271 - 271
Translational PK-PD/TD modeling of antitumor effects and peripheral neuropathy in gemcitabine and nab-paclitaxel chemotherapy from xenograft mice to patients for optimal dose and schedule Shinji KobuchiAtsuko MoritaYukako Ito Original Article 20 December 2023 Pages: 365 - 379
Real-world data on the management of pazopanib-induced liver toxicity in routine care of renal cell cancer and soft tissue sarcoma patients K. WesterdijkS. D. KrensN. P. van Erp Original Article Open access 17 December 2023 Pages: 353 - 364
Safety and pharmacokinetics of imaradenant (AZD4635) in Japanese patients with advanced solid malignancies: a phase I, open-label study Nobuaki MatsubaraShota KusuharaToshio Shimizu Original Article Open access 13 December 2023 Pages: 341 - 352
Enhanced anticancer synergy of LOM612 in combination with selinexor: FOXO1 nuclear translocation-mediated inhibition of Wnt/β-catenin signaling pathway in breast cancer Shengxi XuYingfang ShiSen Li Original Article 05 December 2023 Pages: 191 - 202
Prognostic value of RRM1 and its effect on chemoresistance in pancreatic cancer Xingyi LinYing TanYinting Chen Original Article 01 December 2023 Pages: 237 - 251
Pharmacokinetics and immunogenicity of eftozanermin alfa in subjects with previously-treated solid tumors or hematologic malignancies: results from a phase 1 first-in-human study Carla BiesdorfXiaowen GuanAkshanth R. Polepally Original Article 30 November 2023 Pages: 329 - 339
Quantitative assessment of skin disorders induced by panitumumab: a prospective observational study Hiroaki TakahashiYoko SaitoKenzo Kudo Original Article 28 November 2023 Pages: 319 - 328
Pharmacodynamic effects of the PARP inhibitor talazoparib (MDV3800, BMN 673) in patients with BRCA-mutated advanced solid tumors Arjun MittraGeraldine H. O’ Sullivan CoyneAlice P. Chen Original Article Open access 27 November 2023 Pages: 177 - 189
Azithromycin in cancer treatment: envisioning the probable link of mitochondrial dysfunction and necroptosis Siti Nazihahasma HassanFarizan Ahmad Letter to the Editor 14 November 2023 Pages: 639 - 640
Life-threatening toxicities upon Pembrolizumab intake: could pharmacokinetics be the bad guy? Mourad HamimedRaynier DevillierSamia Harbi Short Communication 13 November 2023 Pages: 627 - 632
Retraction Note: Induction of apoptosis by [6]-gingerol associated with the modulation of p53 and involvement of mitochondrial signaling pathway in B[a]P-induced mouse skin tumorigenesis Nidhi NigamJasmine GeorgeYogeshwer Shukla Retraction Note 13 November 2023 Pages: 269 - 269
Relative bioavailability of fedratinib through various alternative oral administration methods in healthy adults Yizhe ChenDavid WyattGopal Krishna Original Article Open access 13 November 2023 Pages: 307 - 317
CUDC-907 exhibits potent antitumor effects against ovarian cancer through multiple in vivo and in vitro mechanisms Yuanpei WangJing WenFang Ren Original Article 08 November 2023 Pages: 295 - 306
A phase-II study based on dose adjustment according to UGT1A1 polymorphism: is irinotecan underdosed in first-line FOLFIRI regimen for mCRC? Angeline GinzacEmilie ThivatXavier Durando Original Article Open access 07 November 2023 Pages: 225 - 236
Platinum-based chemotherapy in metastatic prostate cancer: what possibilities? Martina CatalanoAndrea LapucciGiandomenico Roviello Review Article Open access 07 November 2023 Pages: 1 - 9
Effect of vitamin E on doxorubicin and paclitaxel-induced memory impairments in male rats Ahmad A. AltarifiKareem SawaliOmar Khabour Original Article 06 November 2023 Pages: 215 - 224
Association between chemotherapy-induced myelosuppression and curative efficacy of 2-cycle chemotherapy in small cell lung cancer Xinyu WangShujun GuXu Qi Original Article 05 November 2023 Pages: 151 - 159
Pharmacokinetic drug–drug interaction between olaparib and apixaban: a case report M. BergeJ. S. GiraudB. Blanchet Letter to the Editor 03 November 2023 Pages: 519 - 521
The combination of brentuximab vedotin and chidamide synergistically suppresses the proliferation of T-cell lymphoma cells through the enhancement of apoptosis Yukio TonozukaHiroshi TanakaYoshihide Kakimoto Original Article Open access 03 November 2023 Pages: 137 - 149
Are novel oral oncolytics underdosed in obese patients? Lishi LinEllen K. O. van der MeerAlwin D. R. Huitema Original Article Open access 31 October 2023 Pages: 129 - 136
Genetic polymorphisms as predictive biomarkers of adverse events during preoperative chemotherapy in esophageal cancer Yao LiangOsamu MaedaYuichi Ando Original Article 28 October 2023 Pages: 121 - 127
Prediction of ROS1 and TRKA/B/C occupancy in plasma and cerebrospinal fluid for entrectinib alone and in DDIs using physiologically based pharmacokinetic (PBPK) modeling approach Liangang ChenNa YaoKai Zhang Original Article 14 October 2023 Pages: 107 - 119
Bidirectional pharmacokinetic drug interactions between olaparib and metformin Joanna Stanisławiak-RudowiczAgnieszka KarbownikEdyta Szałek Original Article Open access 10 October 2023 Pages: 79 - 88
Prospective validation of an equation based on plasma cystatin C for monitoring the glomerular filtration rate in children treated with cisplatin or ifosfamide for cancer Marie LambertMathieu AlonsoEtienne Chatelut Short Communication 03 October 2023 Pages: 393 - 395
Predictive significance of inflammatory markers and mGPS in metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide Sabin Goktas AydinYasin KutluOzcan Yildiz Original Article 29 September 2023 Pages: 71 - 78
Correction to: An IQ consortium analysis of starting dose selection for oncology small molecule first‑in‑patient trials suggests an alternative NOAEL‑based method can be safe while reducing time to the recommended phase 2 dose Bart A. JessenPaul CornwellTimothy Hart Correction Open access 29 September 2023
Long non-coding RNAs: controversial roles in drug resistance of solid tumors mediated by autophagy Mohamed J. SaadhMuhammad Ali Abdulllah AlmoyadReza Akhavan-Sigari Review Article 28 September 2023 Pages: 439 - 453
Sodium orthovanadate exhibits anti-angiogenic, antiapoptotic and blood glucose-lowering effect on colon cancer associated with diabetes Kruti PatelVivek BoraBhoomika Patel Original Article 27 September 2023 Pages: 55 - 70
Polatuzumab vedotin pharmacokinetics in a hemodialysis patient with diffuse large B-cell lymphoma Hajime YasudaNaoko KagaMiki Ando Short Communication 26 September 2023 Pages: 265 - 268
Ivermectin induces nonprotective autophagy by downregulating PAK1 and apoptosis in lung adenocarcinoma cells Man-Yuan LiJiao ZhangHong Zheng Original Article 23 September 2023 Pages: 41 - 54
Correlation analysis between camrelizumab trough concentration levels and efficacy or safety in East Asian patients with advanced lung cancer Mengfei ChengFang YangMei Dong Original Article 23 September 2023 Pages: 31 - 39
A phase I study of the ceramide nanoliposome in patients with advanced solid tumors Aaron CinerTheodore GourdinYixing Jiang Original Article Open access 22 September 2023 Pages: 23 - 29